Prolonged elevation in hippocampal Aβ and cognitive deficits following repeated endotoxin exposure in the mouse

Behavioural Brain Research

Volumn 229, Issue 1, 2012, Pages 176-184

  Kahn, Marielle S ^a   Kranjac, Dinko ^a   Alonzo, Chris A ^a   Haase, Jennifer H ^a   Cedillos, Rudy O ^a   McLinden, Kristina A ^a   Boehm, Gary W ^a   Chumley, Michael J ^a  

^a TEXAS CHRISTIAN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; Cognition; Inflammation; LPS

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ENDOTOXIN; INTERLEUKIN 1BETA;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; INSTRUMENTAL CONDITIONING; MAZE TEST; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WEIGHT REDUCTION;

AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; COGNITION DISORDERS; CONDITIONING (PSYCHOLOGY); DRUG ADMINISTRATION SCHEDULE; ENDOTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXPLORATORY BEHAVIOR; FEAR; HIPPOCAMPUS; INFLAMMATION; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; TIME FACTORS; WEIGHT LOSS;

EID: 84856163870     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.01.010     Document Type: Article

References (52)

1. Heneka M.T., O'Banion M.K. Inflammatory processes in Alzheimer's disease. Journal of Neuroimmunology 2007, 184:69-91.
2. Miklossy J. Chronic inflammation and amyloidgenesis in Alzheimer's disease - role of spirochetes. Journal of Alzheimer's Disease 2008, 13:381-391.
3. Murphy M.P., LeVine H. Alzheimer's disease and the Amyloid peptide. Journal of Alzheimer's Disease 2010, 19:311-323.
4. Minghetti L. Role of inflammation in neurodegenerative diseases. Current Opinion in Neurology 2005, 18:315-321.
5. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., et al. Inflammation and Alzheimer's disease. Neurobiology of Aging 2000, 21:383-421.
6. Hickman S.E., Allsion E.K., El Khoury J. Microglial dysfunction and defective β-Amyloid clearance pathways in aging Alzheimer's disease mice. The Journal of Neuroscience 2008, 28:8354-8360.
7. Jaeger L.B., Dohgu S., Sultana R., Lynch J.L., Owen J.B., Erickson M.A., et al. Lipoplysaccharide alters the blood-brain barrier transport of amyloid β protein: a mechanism for inflammation in the progression of Alzheimer's disease. Brain, Behavior, and Immunity 2009, 23:507-517.
8. Lee J.W., Lee Y.K., Yuk D.Y., Choi D.Y., Ban S.B., Oh K.W., et al. Neuro-inflammation induced by Lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. Journal of Neuroinflammation 2008, 5:37. 10.1186/1742-2094-5-37.
9. Cunningham C., Campion S., Lunnon K., Murray C.L., Woods J., Woods J.F., et al. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biological Psychiatry 2009, 65:304-312.
10. McGeer P.L., McGeer E.G. Inflammation, autotoxicity, and Alzheimer disease. Neurobiology of Aging 2001, 22:799-809.
11. McGeer E.G., McGeer P.L. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. Journal of Alzheimer's Disease 2010, 19:355-361.
12. Kamer A.R., Dasanayake A.P., Craig R.G., Glodzik-Sobanska L., Bry M., de Leon M.J., et al. Alzheimer's disease and peripheral infections: the possible contribution from periodontal infections, model and hypothesis. Journal of Alzheimer's Disease 2008, 13:437-449.
13. Meda L., Cassatella M.A., Szendrel G.I., Otvos L., Baron P., Villalba M., et al. Activation of microglial cells by β-amyloid protein and interferon-γ. Letters to Nature 1995, 374:647-650.
14. Rogers J., Strohmeyer R., Kovelowski C.J., Li R. Microglia and inflammatory mechanisms in the clearance of amyloid β peptide. Glia 2002, 40:260-269.
15. Schwab C., McGeer P. Inflammatory aspects of Alzheimer's disease and other neurodegenerative disorders. Journal of Alzheimer's Disease 2008, 13:159-369.
16. Alzheimer's association of New York: ; October 12, 2011. http://www.alznyc.org/ihave/earlyonset.asp.
17. Jacobsen J.S., Wu C., Redwine J.M., Comery T.A., Arias R., Bowlby M., et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2006, 13:5161-5166.
18. Tuppo E.E., Arias H.R. The role of inflammation in Alzheimer's disease. The International Journal of Biochemistry & Cell Biology 2005, 37:289-305.
19. Engelhart M.J., Geerlings M.I., Meijer J., Kiliaan A., Ruitenberg A., van Swieten J.C., et al. Inflammatory proteins in plasma and the risk of dementia, The Rotterdam Study. Archives of Neurology 2004, 61:668-672.
20. Schmidt R., Schmidt H., Curb J.D., Masaki K., White L.R., Launer L.J., et al. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia aging study. Annals of Neurology 2002, 52:168-174.
21. Aisen P.S., Schafer K.A., Grundman M., Pfeiffer E., Sano M., Davis K.L., et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. The Journal of the American Medical Association 2003, 289:2819-2826.
22. Aisen P.S. Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial. Acta Neurologica Scandinavica. Supplementum 2000, 176:85-89.
23. Sly L.M., Krzesicki R.F., Brashler J.R., Buhl A.E., McKinley, Carter D.B., et al. Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Research Bulletin 2001, 56:581-588.
24. Kranjac D., McLinden K.A., Deodati L.E., Papini M.R., Chumley M.J., Boehm G.W. Peripheral bacterial endotoxin administration triggers both memory consolidation and reconsolidation deficits in mice. Brain, Behavior, and Immunity 2011, 10.1016/j.bbi.2011.08.005.
25. Pugh C.R., Kumagawa K., Fleshner M., Watkins L.R., Maier S.F., Rudy J.W. Selective effects of peripheral lipopolysaccharide administration on contextual and auditory-cue fear conditioning. Brain, Behavior, and Immunity 1998, 12:212-229.
26. Sparkman N.L., Kohman R.A., Garcia A.K., Boehm G.W. Peripheral lipopolysaccharide administration impairs two-way active avoidance conditioning in C57BL/6J mice. Physiology & Behavior 2005, 85:278-288.
27. Cunningham C., Sanderson D.J. Malaise in the water maze: untangling the effects of LPS and IL-1β on learning and memory. Brain, Behavior, and Immunity 2008, 22:1117-1127.
28. Kohman R.A., Tarr A.J., Sparkman N.L., Day C.E., Paquet A., Akkaraju G.R., et al. Alleviation of the effects of endotoxin exposure on behavior and hippocampal IL-1β by a selective non-peptide antagonist of corticotropin-releasing factor receptors. Brain, Behavior, and Immunity 2007, 21:824-835.
29. Sparkman N.L., Kohman R.A., Scott V.J., Boehm G.W. Bacterial endotoxin-induced behavioral alterations in two variations of the Morris water maze. Physiology & Behavior 2005, 86:244-251.
30. Pierson S.N., Butler J.N., Foster R.G. Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. Nucleic Acids Research 2003, 31:e73.
31. Otto T., Poon P. Dorsal hippocampal contributions to unimodal contextual conditioning. Journal of Neuroscience 2006, 26:6603-6609.
32. Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. European Journal of Pharmacology 2004, 500:399-411.
33. Yirmiya R., Goshen I. Immune modulation of learning, memory, neural plasticity, and neurogenesis. Brain, Behavior, and Immunity 2011, 25:181-213.
34. Dantzer R., Kelley K.W. Twenty years of research on cytokine-induced sickness behavior. Brain, Behavior, and Immunity 2007, 21:153-160.
35. Adams B., Fitch T., Chaney S., Gerlai R. Altered performance characteristics in cognitive tasks: comparison of the albino ICR and CD1 mouse strains. Behavioural Brain Research 2002, 133:351-361.
36. Gahtan E., Overmier J.B. Performance more than working memory disrupted by acute systemic inflammation in rats in appetitive tasks. Physiology & Behavior 2001, 73:201-210.
37. Biswas S.K., Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends in Immunology 2009, 30:475-487.
38. West M.A., Heagy W. Endotoxin tolerance: a review. Critical Care Medicine 2002, 30(1 Suppl.):S64-S73.
39. Morgan D. Water maze tasks in mice: special reference to Alzheimer's transgenic mice. Methods of behavior analysis in neuroscience 2009, CRC Press, Boca Raton, FL, [chapter 14]. J.J. Buccafusco (Ed.).
40. Wahlsten D. Mouse behavioral testing: how to use mice in behavioral neuroscience 2011, Academic Press, Jamestown Road, London.
41. Tong L., Balazs R., Thornton P.L., Cotman C.W. β-Amyloid peptide at sublethal concentrations downregulates brain derived neurotrophic factor functions in cultured cortical neurons. The Journal of Neuroscience 2004, 24:6799-6809.
42. Tanaka S., Ide M., Shibutani T., Ohtaki H., Numazawa S., Shioda S., et al. Lipopolysaccharide-induced microglial activation induces learning and memory deficits without neuronal cell death in rats. Journal of Neuroscience 2006, 83:557-566.
43. Shaftel S.S., Kyrkanides S., Olschowka J.A., Miller J.N., Johnson R.E., O'Banion M.K. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. Journal of Clinical Investigation 2007, 117:1595-1604.
44. (1-42) injection causes memeory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT2A levels. Experimental Neurology 2007, 201:164-171.
45. Hölscher C. Diabetes as a risk factor for Alzheimer's disease: insulin signaling impairment in the brain as an alternative model of Alzheimer's disease. Biochemistry Society Transactions 2011, 39:891-897.
46. Itoh A., Akaike T., Sokabe M., Nitta A., Iida R., Olariu A., et al. Impairments of long-term potentiation in hippocampal slices of β-amyloid-infused rats. European Journal of Pharmacology 1999, 382:167-175.
47. Raymond C.R., Ireland D.R., Abraham W.C. NMDA receptor regulation by amyloid-B does not account for its inhibition of LTP in rat hippocampus. Brain Research 2003, 968:263-272.
48. Walsh D.M., Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181-193.
49. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nature Medicine 2008, 14:837-842.
50. Cissé M., Halabisky B., Harris J., Devidze N., Dubal D.B., Sun B., et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 2010, 469:47-52.
51. Palop J.J., Chin J., Roberson E.D., Wang J., Thwin M.T., Bien-Ly N., et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007, 55:697-711.
52. Simon A.M., de Maturana R.L., Ricobaraza A., Escribano L., Schiapparelli L., Cuadrado-Tejedor M., et al. Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease. Journal of Alzheimer's Disease 2009, 17:773-786.